The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Preliminary results from NP40126: Glofitamab and R-CHOP in NHL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, comments on the ongoing, Phase I NP40126 trial (NCT03467373) of glofitamab, a CD20xCD3 T-cell-engaging bispecific antibody, with R-CHOP in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) or treatment naïve diffuse large B-cell lymphoma (DLBCL). A promising safety profile was reported, with a toxicity similar to that of R-CHOP monotherapy, and a reduced rate of cytokine release syndrome (CRS) compared with glofitamab monotherapy. Treatment was additionally administered in a timely fashion, important in curing patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
